CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities
Net loss	$ (34,137)	$ (132,084)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,402	2,926
Amortization and accretion income, net	(31)	31
Share-based compensation	24,254	30,773
Gain on disposal of property and equipment	(96)
Gain on sale of Velusetrag	(2,721)
Amortization of right-of use assets	1,314	1,752
Gain from lease modification	(47)
Undistributed earnings from TRC, LLC	(37,179)	2,986
Interest shortfall on 2035 notes, net	7,372
Other		(168)
Changes in operating assets and liabilities:
Receivables from collaborative and licensing arrangements	1,577	3,648
Prepaid clinical and development services	7,934	4,461
Other prepaid and current assets	2,619	(1,993)
Right-of-use lease asstes	(2,689)
Other assets	(145)	997
Accounts payable	(26)	4,026
Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities	(11,135)	(33,125)
Accrued interest payable	50	(74)
Deferred revenue	(180)	(5,852)
Operating lease liabilities	82	1,718
Other long-term liabilities	(17)
Net cash used in operating activities	(40,799)	(119,978)
Investing activities
Purchases of property and equipment	(363)	(1,923)
Purchases of marketable securities	(53,763)	(40,014)
Maturities of marketable securities	91,699	191,400
Proceeds from the sale of property and equipment	1,866
Net cash provided by investing activities	39,439	149,463
Financing activities
Proceeds from the sale of ordinary shares, net		108,180
Principal payment on 2035 notes		(10,730)
Proceeds from ESPP purchases	487	2,862
Proceeds from option exercises		5
Repurchase of shares to satisfy tax withholding	(1,795)	(6,320)
Net cash (used in) provided by financing activities	(1,308)	93,997
Net increase in cash, cash equivalents, and restricted cash	(2,668)	123,482
Cash, cash equivalents, and restricted cash at beginning of period	90,796	82,300
Cash, cash equivalents, and restricted cash at end of period	88,128	205,782
Supplemental disclosure of cash flow information
Cash paid for interest	15,127	22,490
Cash (received) paid for income taxes, net	$ 25	$ 12